Estrogens and Coronary Artery Disease: New Clinical Perspectives

Advances in Pharmacology

Volumn 77, Issue , 2016, Pages 307-360

  Meyer, M R ^a   Barton, M ^b  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Artery; Atherosclerosis; Blood pressure; Cholesterol; Clinical medicine; Coronary artery disease; Drug therapy; Dyslipidemia; Endothelium; Estrogen; Faslodex ; Fulvestrant; GPER; GPER 1; GPR30; Heart; Hormone replacement therapy; Hormone therapy; Hormones; Hypertension; ICI 182,780; Inflammation; Menopause; Myocardium; Niacin; Nitric oxide; Obesity; Patients; Personalized medicine; Risk factors; Tamoxifen; Theranostics; Vascular

Indexed keywords

CYCLIC AMP; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; NITRIC OXIDE; PROSTANOID; UNCLASSIFIED DRUG; LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL GROWTH; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG APPROVAL; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ESTROGEN ACTIVITY; HOMEOSTASIS; HUMAN; HYPERTENSION; IN VITRO STUDY; MEDICAL GENETICS; NONHUMAN; OBESITY; PERSONALIZED MEDICINE; RISK FACTOR; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECTS; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ESTROGENS; FEMALE; HUMANS; LIGANDS; RECEPTORS, ESTROGEN; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 84979671221     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2016.05.003     Document Type: Chapter

References (314)

1. Abdelhamid, R., Luo, J., Vandevrede, L., Kundu, I., Michalsen, B., Litosh, V.A., Thatcher, G.R., Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chemical Neuroscience 2 (2011), 256–268, 10.1021/cn100106a.
2. Alexander, S.P., Mathie, A., Peters, J.A., Guide to receptors and channels (GRAC). British Journal of Pharmacology 153:Suppl. 2 (2008), S1–S209, 10.1038/sj.bjp.0707746 0707746 [pii] (3rd edition).
3. Altmann, J.B., Yan, G., Meeks, J.F., Abood, M.E., Brailoiu, E., Brailoiu, G.C., G protein-coupled estrogen receptor-mediated effects on cytosolic calcium and nanomechanics in brain microvascular endothelial cells. Journal of Neurochemistry 133 (2015), 629–639, 10.1111/jnc.13066.
4. Arefin, S., Simoncini, T., Wieland, R., Hammarqvist, F., Spina, S., Goglia, L., Kublickiene, K., Vasodilatory effects of the selective GPER agonist G-1 is maximal in arteries of postmenopausal women. Maturitas 78 (2014), 123–130, 10.1016/j.maturitas.2014.04.002.
5. Arnal, J.F., Douin-Echinard, V., Brouchet, L., Tremollieres, F., Laurell, H., Lenfant, F., Gourdy, P., Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundamental & Clinical Pharmacology 20 (2006), 539–548, 10.1111/j.1472-8206.2006.00445.x FCP445 [pii].
6. Aronica, S.M., Kraus, W.L., Katzenellenbogen, B.S., Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proceedings of the National Academy of Sciences of the United States of America 91 (1994), 8517–8521.
7. Bairey Merz, C.N., Johnson, B.D., Sharaf, B.L., Bittner, V., Berga, S.L., Braunstein, G.D., Sopko, G., Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: A report from the NHLBI-sponsored WISE study. Journal of the American College of Cardiology 41 (2003), 413–419.
8. Barrett Mueller, K., Lu, Q., Mohammad, N.N., Luu, V., McCurley, A., Williams, G.H., Jaffe, I.Z., Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology 155 (2014), 4461–4472, 10.1210/en.2014-1270.
9. Barrett-Connor, E., Menopause, atherosclerosis, and coronary artery disease. Current Opinion in Pharmacology 13 (2013), 186–191, 10.1016/j.coph.2013.01.005.
10. Barton, M., Akute Wirkungen von 17β-Oestradiol auf den Tonus menschlicher Arterien in vitro, 1994, Hannover Medical School, Hannover, Germany, 1–79 (Doctor of Medicine (D.M.) dissertation).
11. Barton, M., Postmenopausal oestrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?. Expert Opinion on Investigational Drugs 10 (2001), 789–809, 10.1517/13543784.10.5.789.
12. Barton, M., Reversal of proteinuric renal disease and the emerging role of endothelin. Nature Clinical Practice Nephrology 4 (2008), 490–501, 10.1038/ncpneph0891.
13. Barton, M., Obesity and aging: Determinants of endothelial cell dysfunction and atherosclerosis. Pflügers Archiv 460 (2010), 825–837, 10.1007/s00424-010-0860-y.
14. Barton, M., The discovery of endothelium-dependent contraction: The legacy of Paul M. Vanhoutte. Pharmacological Research 63 (2011), 455–462, 10.1016/j.phrs.2011.02.013.
15. Barton, M., Childhood obesity: A life-long health risk. Acta Pharmacologica Sinica 33 (2012), 189–193, 10.1038/aps.2011.204.
16. Barton, M., Position paper: The membrane estrogen receptor GPER—Clues and questions. Steroids 77 (2012), 935–942, 10.1016/j.steroids.2012.04.001.
17. Barton, M., Cholesterol and atherosclerosis: Modulation by oestrogen. Current Opinion in Lipidology 24 (2013), 214–220, 10.1097/MOL.0b013e3283613a94.
18. Barton, M., Mechanisms and therapy of atherosclerosis and its clinical complications. Current Opinion in Pharmacology 13 (2013), 149–153, 10.1016/j.coph.2013.05.001.
19. Barton, M., Prevention and endothelial therapy of coronary artery disease. Current Opinion in Pharmacology 13 (2013), 226–241, 10.1016/j.coph.2013.05.005.
20. Barton, M., Aging and endothelin: Determinants of disease. Life Sciences 118 (2014), 97–109, 10.1016/j.lfs.2014.09.009.
21. Barton, M., Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER. Steroids, 2016 e-pub January 24.
22. Barton, M., Baretella, O., Meyer, M.R., Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction. British Journal of Pharmacology 165 (2012), 591–602, 10.1111/j.1476-5381.2011.01472.x.
23. Barton, M., Baretella, O., Meyer, M.R., Obesity and risk of vascular disease: Importance of endothelium-derived vasoconstriction. British Journal of Pharmacology 165 (2012), 591–602, 10.1111/j.1476-5381.2011.01472.x.
24. Barton, M., Cremer, J., Mügge, A., 17β-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. European Journal of Pharmacology 362 (1998), 73–76.
25. Barton, M., Dubey, R.K., Postmenopausal hormone-replacement therapy. The New England Journal of Medicine 346 (2002), 63–65.
26. Barton, M., Haudenschild, C.C., d'Uscio, L.V., Shaw, S., Munter, K., Luscher, T.F., Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 14367–14372.
27. Barton, M., Husmann, M., Meyer, M.R., Accelerated vascular aging as a paradigm for hypertensive vascular disease: Prevention and therapy. The Canadian Journal of Cardiology, 32(5), 2016, 10.1016/j.cjca.2016.02.062 680.e4–686.e4.
28. Barton, M., Meyer, M.R., Postmenopausal hypertension: Mechanisms and therapy. Hypertension 54 (2009), 11–18.
29. Barton, M., Meyer, M.R., Nicolaus Copernicus and the rapid vascular responses to aldosterone. Trends in Endocrinology and Metabolism 26 (2015), 396–398, 10.1016/j.tem.2015.05.005.
30. Barton, M., Meyer, M.R., Bhattacharya, I., Haas, E., WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens. BMJ, 335, 2007, 239 http://www.bmj.com/rapid-response/2011/2011/2001/wisdom-trial-postmenopausal-hormone-replacement-and-cardiovascular-events-.
31. Barton, M., Meyer, M.R., Haas, E., Hormone replacement therapy and atherosclerosis in postmenopausal women: Does aging limit therapeutic benefits?. Arteriosclerosis, Thrombosis, and Vascular Biology 27 (2007), 1669–1672.
32. Barton, M., Meyer, M.R., Prossnitz, E.R., Alike but not the same: Anatomic heterogeneity of estrogen receptor-mediated vasodilation. Journal of Cardiovascular Pharmacology 62 (2013), 22–25, 10.1097/FJC.0b013e31829709d4.
33. Barton, M., Prossnitz, E.R., Emerging roles of GPER in diabetes and atherosclerosis. Trends in Endocrinology and Metabolism 26 (2015), 185–192, 10.1016/j.tem.2015.02.003.
34. Beldekas, J.C., Smith, B., Gerstenfeld, L.C., Sonenshein, G.E., Franzblau, C., Effects of 17 beta-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry 20 (1981), 2162–2167.
35. Bhattacharya, I., Damjanovic, M., Hirsiger, S., Haas, E., Gut, A., Mueller-Guerre, L., Barton, M., Selective activation of G-protein coupled estrogen receptor GPR30 inhibits vasoconstriction and induces vascular smooth muscle cell ERK1/2 phosphorylation. Circulation, 116, 2007, II74.
36. Bologa, C.G., Revankar, C.M., Young, S.M., Edwards, B.S., Arterburn, J.B., Kiselyov, A.S., Prossnitz, E.R., Virtual and biomolecular screening converge on a selective agonist for GPR30. Nature Chemical Biology 2 (2006), 207–212.
37. Bonini, J.A., Anderson, S.M., Steiner, D.F., Molecular cloning and tissue expression of a novel orphan G protein-coupled receptor from rat lung. Biochemical and Biophysical Research Communications 234 (1997), 190–193, 10.1006/bbrc.1997.6591.
38. Bowling, M.R., Xing, D., Kapadia, A., Chen, Y.F., Szalai, A.J., Oparil, S., Hage, F.G., Estrogen effects on vascular inflammation are age dependent: Role of estrogen receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 34 (2014), 1477–1485, 10.1161/ATVBAHA.114.303629.
39. Bramlage, P., Wittchen, H.U., Pittrow, D., Kirch, W., Krause, P., Lehnert, H., Sharma, A.M., Recognition and management of overweight and obesity in primary care in Germany. International Journal of Obesity and Related Metabolic Disorders 28 (2004), 1299–1308.
40. Brandes, R.P., Mügge, A., Gender differences in the generation of superoxide anions in the rat aorta. Life Sciences 60 (1997), 391–396.
41. Broughton, B.R., Brait, V.H., Guida, E., Lee, S., Arumugam, T.V., Gardiner-Mann, C.V., Sobey, C.G., Stroke increases g protein-coupled estrogen receptor expression in the brain of male but not female mice. Neurosignals 21 (2013), 229–239, 10.1159/000338019.
42. Broughton, B.R., Brait, V.H., Kim, H.A., Lee, S., Chu, H.X., Gardiner-Mann, C.V., Sobey, C.G., Sex-dependent effects of G protein-coupled estrogen receptor activity on outcome after ischemic stroke. Stroke 45 (2014), 835–841, 10.1161/STROKEAHA.113.001499.
43. Broughton, B.R., Miller, A.A., Sobey, C.G., Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. American Journal of Physiology. Heart and Circulatory Physiology 298 (2010), H1055–H1061.
44. Burke, A.P., Farb, A., Malcom, G., Virmani, R., Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. American Heart Journal 141 (2001), S58–S62.
45. Burns, K.A., Korach, K.S., Estrogen receptors and human disease: An update. Archives of Toxicology 86 (2012), 1491–1504, 10.1007/s00204-012-0868-5.
46. Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., Labarthe, D., Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25 (1995), 305–313.
47. Butenandt, A., Über “Progynon” ein krystallisiertes weibliches Sexualhormon. Die Naturwissenschaften, 17, 1929, 879.
48. Butenandt, A., Über die chemische Untersuchung der Sexualhormone. Zeitschrift für Angewandte Chemie 44 (1931), 905–916.
49. Carmeci, C., Thompson, D.A., Ring, H.Z., Francke, U., Weigel, R.J., Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45 (1997), 607–617.
50. Caroccia, B., Seccia, T.M., Campos, A.G., Gioco, F., Kuppusamy, M., Ceolotto, G., Rossi, G.P., GPER-1 and estrogen receptor-beta ligands modulate aldosterone synthesis. Endocrinology 155 (2014), 4296–4304, 10.1210/en.2014-1416.
51. Caulin-Glaser, T., Garcia-Cardena, G., Sarrel, P., Sessa, W.C., Bender, J.R., 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2 + mobilization. Circulation Research 81 (1997), 885–892.
52. Chambliss, K.L., Yuhanna, I.S., Anderson, R.G., Mendelsohn, M.E., Shaul, P.W., ERbeta has nongenomic action in caveolae. Molecular Endocrinology 16 (2002), 938–946.
53. Chambliss, K.L., Yuhanna, I.S., Mineo, C., Liu, P., German, Z., Sherman, T.S., Shaul, P.W., Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circulation Research 87 (2000), E44–E52.
54. Chang, W.C., Nakao, J., Orimo, H., Murota, S.I., Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochimica et Biophysica Acta 620 (1980), 472–482.
55. Cheng, S.B., Dong, J., Pang, Y., LaRocca, J., Hixon, M., Thomas, P., Filardo, E.J., Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone. Molecular and Cellular Endocrinology 382 (2014), 950–959, 10.1016/j.mce.2013.11.005.
56. Clark, S., Pollard, K., Rainville, J., Vasudevan, N., Detection of the phosphorylation of the estrogen receptor alpha as an outcome of GPR30 activation. Methods in Molecular Biology 1366 (2016), 457–470, 10.1007/978-1-4939-3127-9_36.
57. Clarkson, T.B., Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14 (2007), 373–384.
58. Collins, P., Mosca, L., Geiger, M.J., Grady, D., Kornitzer, M., Amewou-Atisso, M.G., Wenger, N.K., Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial. Results of subgroup analyses by age and other factors. Circulation 119 (2009), 922–930.
59. Collins, P., Rosano, G.M., Sarrel, P.M., Ulrich, L., Adamopoulos, S., Beale, C.M., Poole-Wilson, P.A., 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92 (1995), 24–30.
60. Crandall, C.J., Barrett-Connor, E., Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: A systematic review. Endocrinology and Metabolism Clinics of North America 42 (2013), 227–253, 10.1016/j.ecl.2013.02.003.
61. Cruz, M.N., Agewall, S., Schenck-Gustafsson, K., Kublickiene, K., Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis 196 (2008), 49–58, 10.1016/j.atherosclerosis.2007.01.038.
62. Cummings, S.R., Ensrud, K., Delmas, P.D., LaCroix, A.Z., Vukicevic, S., Reid, D.M., Investigators, P.S., Lasofoxifene in postmenopausal women with osteoporosis. The New England Journal of Medicine 362 (2010), 686–696, 10.1056/NEJMoa0808692.
63. Davis, K.E., Carstens, E.J., Irani, B.G., Gent, L.M., Hahner, L.M., Clegg, D.J., Sexually dimorphic role of G protein-coupled estrogen receptor (GPER) in modulating energy homeostasis. Hormones and Behavior 66 (2014), 196–207, 10.1016/j.yhbeh.2014.02.004.
64. De Francesco, E.M., Angelone, T., Pasqua, T., Pupo, M., Cerra, M.C., Maggiolini, M., GPER mediates cardiotropic effects in spontaneously hypertensive rat hearts. PLoS One, 8, 2013, e69322, 10.1371/journal.pone.0069322.
65. De Leo, V., la Marca, A., Morgante, G., Lanzetta, D., Setacci, C., Petraglia, F., Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. American Journal of Obstetrics and Gynecology 184 (2001), 350–353, 10.1067/mob.2001.111065.
66. Dennis, M.K., Burai, R., Ramesh, C., Petrie, W.K., Alcon, S.N., Nayak, T.K., Prossnitz, E.R., In vivo effects of a GPR30 antagonist. Nature Chemical Biology 5 (2009), 421–427, 10.1038/nchembio.168 nchembio.168 [pii].
67. Dennis, M.K., Field, A.S., Burai, R., Ramesh, C., Petrie, W.K., Bologa, C.G., Prossnitz, E.R., Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. The Journal of Steroid Biochemistry and Molecular Biology 127 (2011), 358–366, 10.1016/j.jsbmb.2011.07.002 S0960-0760(11)00147-6 [pii].
68. Deroo, B.J., Korach, K.S., Estrogen receptors and human disease. The Journal of Clinical Investigation 116 (2006), 561–570, 10.1172/JCI27987.
69. de Valk-de Roo, G.W., Stehouwer, C.D., Meijer, P., Mijatovic, V., Kluft, C., Kenemans, P., Netelenbos, C., Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arteriosclerosis, Thrombosis, and Vascular Biology 19 (1999), 2993–3000.
70. Dhandapani, K.M., Brann, D.W., Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biology of Reproduction 67 (2002), 1379–1385.
71. Dubey, R.K., Imthurn, B., Barton, M., Jackson, E.K., Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovascular Research 66 (2005), 295–306, 10.1016/j.cardiores.2004.12.012.
72. Elhage, R., Clamens, S., Reardon-Alulis, C., Getz, G.S., Fievet, C., Maret, A., Bayard, F., Loss of atheroprotective effect of estradiol in immunodeficient mice. Endocrinology 141 (2000), 462–465.
73. Elhage, R., Gourdy, P., Jawien, J., Brouchet, L., Castano, C., Fievet, C., Bayard, F., The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity. The American Journal of Pathology 167 (2005), 267–274 167/1/267 [pii].
74. El-Mowafy, A.M., White, R.E., Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS Letters 451 (1999), 63–67.
75. Ensrud, K., LaCroix, A., Thompson, J.R., Thompson, D.D., Eastell, R., Reid, D.M., Cummings, S., Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial. Circulation 122 (2010), 1716–1724, 10.1161/CIRCULATIONAHA.109.924571.
76. Evans, N.J., Bayliss, A.L., Reale, V., Evans, P.D., Characterisation of signalling by the endogenous GPER1 (GPR30) receptor in an embryonic mouse hippocampal cell line (mHippoE-18). PLoS One, 11, 2016, e0152138, 10.1371/journal.pone.0152138.
77. Farhat, M.Y., Abi-Younes, S., Dingaan, B., Vargas, R., Ramwell, P.W., Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism. The Journal of Pharmacology and Experimental Therapeutics 276 (1996), 652–657.
78. Farhat, M.Y., Lavigne, M.C., Ramwell, P.W., The vascular protective effects of estrogen. FASEB Journal 10 (1996), 615–624.
79. Feldman, R.D., Gros, R., Ding, Q., Hussain, Y., Ban, M.R., McIntyre, A.D., Hegele, R.A., A common hypofunctional genetic variant of GPER is associated with increased blood pressure in women. British Journal of Clinical Pharmacology 78 (2014), 1441–1452, 10.1111/bcp.12471.
80. Feletou, M., Vanhoutte, P.M., Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). American Journal of Physiology. Heart and Circulatory Physiology 291 (2006), H985–H1002.
81. Feng, Y., Gregor, P., Cloning of a novel member of the G protein-coupled receptor family related to peptide receptors. Biochemical and Biophysical Research Communications 231 (1997), 651–654, 10.1006/bbrc.1997.6161.
82. Filardo, E.J., Quinn, J.A., Bland, K.I., Frackelton, A.R. Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Molecular Endocrinology 14 (2000), 1649–1660.
83. Filardo, E.J., Quinn, J.A., Frackelton, A.R. Jr., Bland, K.I., Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Molecular Endocrinology 16 (2002), 70–84.
84. Filice, E., Recchia, A.G., Pellegrino, D., Angelone, T., Maggiolini, M., Cerra, M.C., A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. Journal of Physiology and Pharmacology 60 (2009), 3–10.
85. Foegh, M.L., Zhao, Y., Farhat, M., Ramwell, P.W., Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Ciba Foundation Symposium 191 (1995), 139–145 discussion 145–139.
86. Ford, J., Hajibeigi, A., Long, M., Hahner, L., Gore, C., Hsieh, J.T., Oz, O.K., GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. Journal of Bone and Mineral Research 26 (2011), 298–307, 10.1002/jbmr.209.
87. Fujio, Y., Yamada, F., Takahashi, K., Shibata, N., Responses of smooth muscle cells to platelet-derived growth factor are inhibited by herbimycin-A tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications 195 (1993), 79–83, 10.1006/bbrc.1993.2012.
88. Fuller, P.J., Young, M.J., Duelling receptors: Estrogen receptor versus mineralocorticoid receptor in the cardiovascular system. Endocrinology 155 (2014), 4117–4119, 10.1210/en.2014-1778.
89. Furchgott, R.F., Studies on relaxation of rabbit aorta by sodium nitrite: The basis for the proposal that acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. Vanhoutte, P.M., (eds.) Vasodilation: Vascular smooth muscle, peptides, autonomic nerves and endothelium, 1988, Raven Press, New York, 401–414.
90. Furchgott, R.F., Zawadzki, J.V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980), 373–376.
91. Gambacciani, M., Monteleone, P., Vitale, C., Silvestri, A., Fini, M., Genazzani, A.R., Rosano, G.M., Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: A randomised clinical trial. Maturitas 43 (2002), 117–123.
92. Gaudet, H.M., Cheng, S.B., Christensen, E.M., Filardo, E.J., The G-protein coupled estrogen receptor, GPER: The inside and inside-out story. Molecular and Cellular Endocrinology 418:Pt. 3 (2015), 207–219, 10.1016/j.mce.2015.07.016.
93. Gerhard, M., Walsh, B.W., Tawakol, A., Haley, E.A., Creager, S.J., Seely, E.W., Creager, M.A., Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98 (1998), 1158–1163.
94. Gille, A., Bodor, E.T., Ahmed, K., Offermanns, S., Nicotinic acid: Pharmacological effects and mechanisms of action. Annual Review of Pharmacology and Toxicology 48 (2008), 79–106, 10.1146/annurev.pharmtox.48.113006.094746.
95. Gimbrone, M.A. Jr., Garcia-Cardena, G., Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circulation Research 118 (2016), 620–636, 10.1161/CIRCRESAHA.115.306301.
96. Giordano, S., Hage, F.G., Xing, D., Chen, Y.F., Allon, S., Chen, C., Oparil, S., Estrogen and cardiovascular disease: Is timing everything?. The American Journal of the Medical Sciences 350 (2015), 27–35, 10.1097/MAJ.0000000000000512.
97. Gisclard, V., Flavahan, N.A., Vanhoutte, P.M., Alpha adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17 beta-estradiol. The Journal of Pharmacology and Experimental Therapeutics 240 (1987), 466–470.
98. Gisclard, V., Miller, V.M., Vanhoutte, P.M., Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. The Journal of Pharmacology and Experimental Therapeutics 244 (1988), 19–22.
99. Gollasch, M., Vasodilator signals from perivascular adipose tissue. British Journal of Pharmacology 165 (2012), 633–642, 10.1111/j.1476-5381.2011.01430.x.
100. Grady, D., Rubin, S.M., Petitti, D.B., Fox, C.S., Black, D., Ettinger, B., Cummings, S.R., Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine 117 (1992), 1016–1037.
101. Grainger, D.J., Weissberg, P.L., Metcalfe, J.C., Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. The Biochemical Journal 294:Pt. 1 (1993), 109–112.
102. Green, S., Walter, P., Greene, G., Krust, A., Goffin, C., Jensen, E., Chambon, P., Cloning of the human oestrogen receptor cDNA. Journal of Steroid Biochemistry 24 (1986), 77–83.
103. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P., Chambon, P., Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320 (1986), 134–139, 10.1038/320134a0.
104. Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., Shine, J., Sequence and expression of human estrogen receptor complementary DNA. Science 231 (1986), 1150–1154.
105. Gros, R., Ding, Q., Liu, B., Chorazyczewski, J., Feldman, R.D., Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. American Journal of Physiology. Cell Physiology 304 (2013), C532–C540, 10.1152/ajpcell.00203.2012.
106. Gros, R., Ding, Q., Sklar, L.A., Prossnitz, E.E., Arterburn, J.B., Chorazyczewski, J., Feldman, R.D., GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 57 (2011), 442–451, 10.1161/HYPERTENSIONAHA.110.161653 HYPERTENSIONAHA.110.161653 [pii].
107. Gruber, C.J., Tschugguel, W., Schneeberger, C., Huber, J.C., Production and actions of estrogens. The New England Journal of Medicine 346 (2002), 340–352.
108. Guo, X., Razandi, M., Pedram, A., Kassab, G., Levin, E.R., Estrogen induces vascular wall dilation: Mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. The Journal of Biological Chemistry 280 (2005), 19704–19710, 10.1074/jbc.M501244200 M501244200 [pii].
109. Guzic-Salobir, B., Keber, I., Seljeflot, I., Arnesen, H., Vrabic, L., Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. Journal of Internal Medicine 250 (2001), 508–515.
110. Haas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G.C., Gao, X., Barton, M., Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circulation Research 104 (2009), 288–291, 10.1161/CIRCRESAHA.108.190892 CIRCRESAHA.108.190892 [pii].
111. Haas, E., Meyer, M.R., Schurr, U., Bhattacharya, I., Minotti, R., Nguyen, H.H., Barton, M., Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 49 (2007), 1358–1363.
112. Han, G., White, R.E., G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease. World Journal of Cardiology 6 (2014), 367–375, 10.4330/wjc.v6.i6.367.
113. Hansson, G.K., Immune mechanisms in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 21 (2001), 1876–1890.
114. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 352 (2005), 1685–1695.
115. Hansson, G.K., Libby, P., The immune response in atherosclerosis: A double-edged sword. Nature Reviews Immunology 6 (2006), 508–519, 10.1038/nri1882 nri1882 [pii].
116. Harada, N., Sasano, H., Murakami, H., Ohkuma, T., Nagura, H., Takagi, Y., Localized expression of aromatase in human vascular tissues. Circulation Research 84 (1999), 1285–1291.
117. Harman, S.M., Vittinghoff, E., Brinton, E.A., Budoff, M.J., Cedars, M.I., Lobo, R.A., Black, D.M., Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. The American Journal of Medicine 124 (2010), 199–205, 10.1016/j.amjmed.2010.09.021.
118. Hasbi, A., O'Dowd, B.F., George, S.R., A G protein-coupled receptor for estrogen: The end of the search?. Molecular Interventions 5 (2005), 158–161, 10.1124/mi.5.3.5.
119. Haynes, M.P., Sinha, D., Russell, K.S., Collinge, M., Fulton, D., Morales-Ruiz, M., Bender, J.R., Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circulation Research 87 (2000), 677–682.
120. Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., Butler, J., Dracup, K., Ezekowitz, M.D., … Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 123 (2011), 933–944, 10.1161/CIR.0b013e31820a55f5.
121. Hevener, A.L., Clegg, D.J., Mauvais-Jarvis, F., Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome. Molecular and Cellular Endocrinology 418:Pt 3 (2015), 306–321, 10.1016/j.mce.2015.05.020.
122. Hewitt, S.C., Korach, K.S., Estrogen receptors: Structure, mechanisms and function. Reviews in Endocrine & Metabolic Disorders 3 (2002), 193–200.
123. Hewitt, S.C., Winuthayanon, W., Korach, K.S., What's new in estrogen receptor action in the female reproductive tract. Journal of Molecular Endocrinology 56 (2016), R55–R71, 10.1530/JME-15-0254.
124. Hill, B.J., Gebre, S., Schlicker, B., Jordan, R., Necessary, S., Nongenomic inhibition of coronary constriction by 17ss-estradiol, 2-hydroxyestradiol, and 2-methoxyestradiol. Canadian Journal of Physiology and Pharmacology 88 (2010), 147–152, 10.1139/Y09-120.
125. Hodgin, J.B., Krege, J.H., Reddick, R.L., Korach, K.S., Smithies, O., Maeda, N., Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in ApoE-/- mice. The Journal of Clinical Investigation 107 (2001), 333–340.
126. Hodis, H.N., Mack, W.J., Henderson, V.W., Shoupe, D., Budoff, M.J., Hwang-Levine, J., .. for the ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. The New England Journal of Medicine 374 (2016), 1221–1231, 10.1056/NEJMoa1505241.
127. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280 (1998), 605–613.
128. Hussain, Y., Ding, Q., Connelly, P.W., Brunt, J.H., Ban, M.R., McIntyre, A.D., Feldman, R.D., G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: Cellular and population genetic studies. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (2015), 213–221, 10.1161/ATVBAHA.114.304326.
129. Iafrati, M.D., Karas, R.H., Aronovitz, M., Kim, S., Sullivan, T.R. Jr., Lubahn, D.B., Mendelsohn, M.E., Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Medicine 3 (1997), 545–548.
130. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G., Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 84 (1987), 9265–9269.
131. Ikeda, Y., Tajima, S., Izawa-Ishizawa, Y., Kihira, Y., Ishizawa, K., Tomita, S., Tamaki, T., Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLoS One, 7, 2012, e40465, 10.1371/journal.pone.0040465.
132. Iorga, A., Li, J., Sharma, S., Umar, S., Bopassa, J.C., Nadadur, R.D., Eghbali, M., Rescue of pressure overload-induced heart failure by estrogen therapy. Journal of the American Heart Association, 2016, 5, 10.1161/JAHA.115.002482.
133. Isles, C.G., Hole, D.J., Hawthorne, V.M., Lever, A.F., Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men. Lancet 339 (1992), 702–706.
134. Jang, E.J., Seok, Y.M., Arterburn, J.B., Olatunji, L.A., Kim, I.K., GPER-1 agonist G1 induces vasorelaxation through activation of epidermal growth factor receptor-dependent signalling pathway. The Journal of Pharmacy and Pharmacology 65 (2013), 1488–1499, 10.1111/jphp.12113.
135. Jensen, E.V., DeSombre, E.R., Estrogen-receptor interaction. Science 182 (1973), 126–134.
136. Jensen, E., A conversation with Elwood Jensen. Interview by David D. Moore. Annual Reviews in Physiology 74 (2014), 1–11, 10.1146/annurev-physiol-020911-153327.
137. Jensen, E.V., Jacobson, H.I., Fate of steroid estrogens in target tissues. Pincus, G., Vollmer, E., (eds.) Biological activities of steroids in relation to cancer, 1960, Academic, New York, 161–174.
138. Jensen, E.V., Desombre, E.R., Hurst, D.J., Kawashima, T., Jungblut, P.W., Estrogen-receptor interactions in target tissues. Archives d'Anatomie Microscopique et de Morphologie Expérimentale 56 (1967), 547–569.
139. Jessup, J.A., Lindsey, S.H., Wang, H., Chappell, M.C., Groban, L., Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One, 5, 2010, e15433, 10.1371/journal.pone.0015433.
140. Jia, B., Gao, Y., Li, M., Shi, J., Peng, Y., Du, X., Zhang, J., GPR30 promotes prostate stromal cell activation via suppression of ERα expression and its downstream signaling pathway. Endocrinology, 2016 http://dx.doi.org/en20161035 epub May 10.
141. Kabir, M.E., Singh, H., Lu, R., Olde, B., Leeb-Lundberg, L.M., Bopassa, J.C., G Protein-coupled estrogen receptor 1 mediates acute estrogen-induced cardioprotection via MEK/ERK/GSK-3 beta pathway after ischemia/reperfusion. PLoS One, 10, 2015, e0135988, 10.1371/journal.pone.0135988.
142. Kang, S., Liu, Y., Sun, D., Zhou, C., Liu, A., Xu, C., Sun, H., Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLoS One, 7, 2012, e48185, 10.1371/journal.pone.0048185.
143. Karas, R.H., Hodgin, J.B., Kwoun, M., Krege, J.H., Aronovitz, M., Mackey, W., Mendelsohn, M.E., Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proceedings of the National Academy of Sciences of the United States of America 96 (1999), 15133–15136.
144. Karas, R.H., Mendelsohn, M.E., Rapid vasomotor effects of estrogen: Men are part of the club. Chest 114 (1998), 1508–1509.
145. Karas, R.H., Schulten, H., Pare, G., Aronovitz, M.J., Ohlsson, C., Gustafsson, J.A., Mendelsohn, M.E., Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circulation Research 89 (2001), 534–539.
146. Khalil, R.A., Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochemical Pharmacology 86 (2013), 1627–1642, 10.1016/j.bcp.2013.09.024.
147. Keaney, J.F. Jr., Solomon, C.G., Postmenopausal hormone therapy and atherosclerosis—Time is of the essence. The New England Journal of Medicine 374 (2016), 1279–1280, 10.1056/NEJMe1602846.
148. Kimura, M., Mizukami, Y., Miura, T., Fujimoto, K., Kobayashi, S., Matsuzaki, M., Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/Bax pathway during ischemic hypoxia and reoxygenation. The Journal of Biological Chemistry 276 (2001), 26453–26460, 10.1074/jbc.M101289200.
149. Kok, H.S., van Asselt, K.M., van der Schouw, Y.T., van der Tweel, I., Peeters, P.H., Wilson, P.W., Grobbee, D.E., Heart disease risk determines menopausal age rather than the reverse. Journal of the American College of Cardiology 47 (2006), 1976–1983.
150. Komesaroff, P.A., Fullerton, M., Esler, M.D., Dart, A., Jennings, G., Sudhir, K., Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 38 (2001), 1011–1016.
151. Kublickiene, K., Fu, X.D., Svedas, E., Landgren, B.M., Genazzani, A.R., Simoncini, T., Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. The Journal of Clinical Endocrinology and Metabolism 93 (2008), 1874–1883, 10.1210/jc.2007-2651.
152. Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.Å., Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the United States of America 93 (1996), 5925–5930.
153. Kvingedal, A.M., Smeland, E.B., A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Letters 407 (1997), 59–62 doi:S0014-5793(97)00278-0 [pii].
154. Lafferty, A.R., Torpy, D.J., Stowasser, M., Taymans, S.E., Lin, J.P., Huggard, P., Stratakis, C.A., A novel genetic locus for low renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22). Journal of Medical Genetics 37 (2000), 831–835.
155. Lafont, A.G., Rousseau, K., Tomkiewicz, J., Dufour, S., Three nuclear and two membrane estrogen receptors in basal teleosts, Anguilla sp.: Identification, evolutionary history and differential expression regulation. General and Comparative Endocrinology, 2016, 10.1016/j.ygcen.2015.11.021 (in press).
156. Lakatta, E.G., So! What's aging? Is cardiovascular aging a disease?. Journal of Molecular and Cellular Cardiology 83 (2015), 1–13, 10.1016/j.yjmcc.2015.04.005.
157. Landahl, S., Bengtsson, C., Sigurdsson, J.A., Svanborg, A., Svardsudd, K., Age-related changes in blood pressure. Hypertension 8 (1986), 1044–1049.
158. Lee, T.M., Lin, S.Z., Chang, N.C., Both GPER and membrane oestrogen receptor-alpha activation protect ventricular remodelling in 17beta oestradiol-treated ovariectomized infarcted rats. Journal of Cellular and Molecular Medicine 18 (2014), 2454–2465, 10.1111/jcmm.12430.
159. Lee, S.L., Wang, W.W., Lanzillo, J.J., Fanburg, B.L., Regulation of serotonin-induced DNA synthesis of bovine pulmonary artery smooth muscle cells. The American Journal of Physiology 266 (1994), L53–L60.
160. Lenhart, P.M., Broselid, S., Barrick, C.J., Leeb-Lundberg, L.M., Caron, K.M., G-protein-coupled receptor 30 interacts with receptor activity-modifying protein 3 and confers sex-dependent cardioprotection. Journal of Molecular Endocrinology 51 (2013), 191–202, 10.1530/JME-13-0021.
161. Lew, R., Komesaroff, P., Williams, M., Dawood, T., Sudhir, K., Endogenous estrogens influence endothelial function in young men. Circulation Research 93 (2003), 1127–1133.
162. Li, F., Yu, X., Szynkarski, C.K., Meng, C., Zhou, B., Barhoumi, R., Han, G., Activation of GPER induces differentiation and inhibition of coronary artery smooth muscle cell proliferation. PLoS One, 8, 2013, e64771, 10.1371/journal.pone.0064771.
163. Libby, P., Inflammation and cardiovascular disease mechanisms. The American Journal of Clinical Nutrition 83 (2006), 456S–460S.
164. Libby, P., Collagenases and cracks in the plaque. The Journal of Clinical Investigation 123 (2013), 3201–3203, 10.1172/JCI67526.
165. Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis. Circulation 105 (2002), 1135–1143.
166. Lieberman, E.H., Gerhard, M.D., Uehata, A., Walsh, B.W., Selwyn, A.P., Ganz, P., Creager, M.A., Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Annals of Internal Medicine 121 (1994), 936–941.
167. Lim, S.C., Caballero, A.E., Arora, S., Smakowski, P., Bashoff, E.M., Brown, F.M., Veves, A., The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 84 (1999), 4159–4164, 10.1210/jcem.84.11.6160.
168. Lindsey, S.H., Carver, K.A., Prossnitz, E.R., Chappell, M.C., Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. Journal of Cardiovascular Pharmacology, 2011, 10.1097/FJC.0b013e3182135f1c.
169. Lindsey, S.H., Cohen, J.A., Brosnihan, K.B., Gallagher, P.E., Chappell, M.C., Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150 (2009), 3753–3758.
170. Lindsey, S.H., Liu, L., Chappell, M.C., Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling. Steroids 81 (2014), 99–102, 10.1016/j.steroids.2013.10.017.
171. Lindsey, S.H., Yamaleyeva, L.M., Brosnihan, K.B., Gallagher, P.E., Chappell, M.C., Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2.Lewis rat. Hypertension 58 (2011), 665–671, 10.1161/HYPERTENSIONAHA.111.175174.
172. Liu, L., Kashyap, S., Murphy, B., Hutson, D.D., Budish, R.A., Trimmer, E.H., Lindsey, S.H., GPER activation ameliorates aortic remodeling induced by salt-sensitive hypertension. American journal of physiology. Heart and Circulatory Physiology 310 (2016), H953–H961, 10.1152/ajpheart.00631.2015.
173. Liu, S., Kilic, G., Meyers, M.S., Navarro, G., Wang, Y., Oberholzer, J., Mauvais-Jarvis, F., Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia 56 (2013), 370–381, 10.1007/s00125-012-2764-1.
174. Locher, R., Emmanuele, L., Suter, P.M., Vetter, W., Barton, M., Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. European Journal of Pharmacology 434 (2002), 1–7.
175. Löhn, M., Dubrovska, G., Lauterbach, B., Luft, F.C., Gollasch, M., Sharma, A.M., Periadventitial fat releases a vascular relaxing factor. FASEB Journal 16 (2002), 1057–1063, 10.1096/fj.02-0024com.
176. Louet, J.F., LeMay, C., Mauvais-Jarvis, F., Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Current Atherosclerosis Reports 6 (2004), 180–185.
177. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V.,.. Memish, Z.A., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128, 10.1016/S0140-6736(12)61728-0.
178. Madak-Erdogan, Z., Kim, S.H., Gong, P., Zhao, Y.C., Zhang, H., Chambliss, K.L.,.. Katzenellenbogen, B.S., Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues. Science Signaling, 9, 2016, 10.1126/scisignal.aad8170 ra53.
179. Maddox, Y.T., Falcon, J.G., Ridinger, M., Cunard, C.M., Ramwell, P.W., Endothelium-dependent gender differences in the response of the rat aorta. The Journal of Pharmacology and Experimental Therapeutics 240 (1987), 392–395.
180. Mårtensson, U.E., Salehi, S.A., Windahl, S., Gomez, M.F., Sward, K., Daszkiewicz-Nilsson, J., Leeb-Lundberg, L.M., Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150 (2009), 687–698, 10.1210/en.2008-0623 en.2008-0623 [pii].
181. Mata, K.M., Li, W., Reslan, O.M., Siddiqui, W.T., Opsasnick, L.A., Khalil, R.A., Adaptive increases in expression and vasodilator activity of estrogen receptor subtypes in a blood vessel-specific pattern during pregnancy. American Journal of Physiology. Heart and Circulatory Physiology 309 (2015), H1679–H1696, 10.1152/ajpheart.00532.2015.
182. Matthews, J., Gustafsson, J.A., Estrogen signaling: A subtle balance between ER alpha and ER beta. Molecular Interventions 3 (2003), 281–292.
183. Mauvais-Jarvis, F., Clegg, D.J., Hevener, A.L., The role of estrogens in control of energy balance and glucose homeostasis. Endocrine Reviews 34 (2013), 309–338, 10.1210/er.2012-1055.
184. Maximov, P.Y., Lee, T.M., Jordan, V.C., The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Current Clinical Pharmacology 8 (2013), 135–155.
185. Mazzuca, M.Q., Mata, K.M., Li, W., Rangan, S.S., Khalil, R.A., Estrogen receptor subtypes mediate distinct microvascular dilation and reduction in [Ca2 +]I in mesenteric microvessels of female rat. The Journal of Pharmacology and Experimental Therapeutics 352 (2015), 291–304, 10.1124/jpet.114.219865.
186. McCoy, R.L., Perlemutter, D.H., Cloning of novel IL8-related receptors from human hepatic tissue: Human IL8-related receptor (DRY12) mRNA, complete codons. 1996 Submitted June 1996 to the EMBL/GenBank/DDBJ databases. Genbank accession code U58828.
187. McGill, H.C.J., McMahan, C.A., Herderick, E.E., Zieske, A.W., Malcom, G.T., Tracy, R.E., Strong, J.P., Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105 (2002), 2712–2718.
188. McSweeney, J.C., Rosenfeld, A.G., Abel, W.M., Braun, L.T., Burke, L.E., Daugherty, S.L., on behalf of the American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research. Preventing and experiencing ischemic heart disease as a woman: State of the science—A scientific statement from the American Heart Association. Circulation 133 (2016), 1302–1331, 10.1161/CIR.0000000000000381.
189. Menazza, S., Murphy, E., The expanding complexity of estrogen receptor signaling in the cardiovascular system. Circulation Research 118 (2016), 994–1007.
190. Mendelsohn, M.E., Karas, R.H., The protective effects of estrogen on the cardiovascular system. The New England Journal of Medicine 340 (1999), 1801–1811.
191. Mendelsohn, M.E., Karas, R.H., Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005), 1583–1587.
192. Mendizabal, Y., Llorens, S., Nava, E., Vasoactive effects of prostaglandins from the perivascular fat of mesenteric resistance arteries in WKY and SHROB rats. Life Sciences 93 (2013), 1023–1032, 10.1016/j.lfs.2013.10.021.
193. Merz, C.N., Johnson, B.D., Berga, S., Braunstein, G., Reis, S.E., Bittner, V., Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: Data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertility and Sterility 85 (2006), 1425–1431.
194. Meyer, M.R., Amann, K., Field, A.S., Hu, C., Hathaway, H.J., Kanagy, N.L., Prossnitz, E.R., Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction. Hypertension 59 (2012), 507–512, 10.1161/HYPERTENSIONAHA.111.184606.
195. Meyer, M.R., Baretella, O., Prossnitz, E.R., Barton, M., Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 86 (2010), 58–64.
196. Meyer, M.R., Barton, M., ERα, ERβ, and gpER: Novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovascular Research 83 (2009), 605–610, 10.1093/cvr/cvp187.
197. Meyer, M.R., Clegg, D.J., Prossnitz, E.R., Barton, M., Obesity, insulin resistance and diabetes: Sex differences and role of oestrogen receptors. Acta Physiologica (Oxford, England) 203 (2011), 259–269, 10.1111/j.1748-1716.2010.02237.x.
198. Meyer, M.R., Field, A.S., Kanagy, N.L., Barton, M., Prossnitz, E.R., GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sciences 91 (2012), 623–627, 10.1016/j.lfs.2012.01.007.
199. Meyer, M.R., Fredette, N.C., Barton, M., Prossnitz, E.R., Regulation of vascular smooth muscle tone by adipose-derived contracting factor. PLoS One, 8, 2013, e79245, 10.1371/journal.pone.0079245.
200. Meyer, M.R., Fredette, N.C., Barton, M., Prossnitz, E.R., G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity. The Journal of Endocrinology 227 (2015), 61–69, 10.1530/JOE-15-0257.
201. Meyer, M.R., Fredette, N.C., Howard, T., Hu, C., Ramesh, C., Daniel, C., Prossnitz, E.R., G protein-coupled estrogen receptor protects from atherosclerosis. Scientific Reports, 4, 2014, 7564 Erratum in: Scientific Reports, 7565 (2015) 13510.
202. Meyer, M.R., Fredette, N.C., Sharma, G., Barton, M., Prossnitz, E.R., GPER is required for the age-dependent upregulation of the myocardial endothelin system. Life Sciences, 2016, 10.1016/j.lfs.2016.02.041.
203. Meyer, M.R., Haas, E., Barton, M., Gender differences of cardiovascular disease: New perspectives for estrogen receptor signaling. Hypertension 47 (2006), 1019–1026.
204. Meyer, M.R., Haas, E., Barton, M., Need for research on estrogen receptor function: Importance for postmenopausal hormone therapy and atherosclerosis. Gender Medicine 5:Suppl. A (2008), S19–S33.
205. Meyer, M.R., Haas, E., Prossnitz, E.R., Barton, M., Non-genomic regulation of vascular cell function and growth by estrogen. Molecular and Cellular Endocrinology 308 (2009), 9–16.
206. Meyer, M.R., Prossnitz, E.R., Barton, M., The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascular Pharmacology 55 (2011), 17–25, 10.1016/j.vph.2011.06.003 S1537-1891(11)00064-4 [pii].
207. Meyers, M.J., Sun, J., Carlson, K.E., Marriner, G.A., Katzenellenbogen, B.S., Katzenellenbogen, J.A., Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. Journal of Medicinal Chemistry 44 (2001), 4230–4251.
208. Miller, V.M., Duckles, S.P., Vascular actions of estrogens: Functional implications. Pharmacological Reviews 60 (2008), 210–241.
209. Miller, V.M., Vanhoutte, P.M., 17 beta-Estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. The American Journal of Physiology 258 (1990), R1502–R1507.
210. Miller, A.P., Xing, D., Feng, W., Fintel, M., Chen, Y.F., Oparil, S., Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 14 (2007), 251–260.
211. Minson, C.T., Halliwill, J.R., Young, T.M., Joyner, M.J., Influence of the menstrual cycle on sympathetic activity, baroreflex sensitivity, and vascular transduction in young women. Circulation 101 (2000), 862–868.
212. Mizutani, K., Ikeda, K., Yamori, Y., Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochemical and Biophysical Research Communications 274 (2000), 61–67, 10.1006/bbrc.2000.3097.
213. Moreno-Ulloa, A., Mendez-Luna, D., Beltran-Partida, E., Castillo, C., Guevara, G., Ramirez-Sanchez, I., Villarreal, F., The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER). Pharmacological Research 100 (2015), 309–320, 10.1016/j.phrs.2015.08.014.
214. Mosselman, S., Polman, J., Dijkema, R., ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Letters 392 (1996), 49–53.
215. Mucowski, S.J., Mack, W.J., Shoupe, D., Kono, N., Paulson, R., Hodis, H.N., Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women. Fertility and Sterility 101 (2014), 1117–1122, 10.1016/j.fertnstert.2013.12.055.
216. Mügge, A., Riedel, M., Barton, M., Kuhn, M., Lichtlen, P.R., Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovascular Research 27 (1993), 1939–1942.
217. Mügge, A., Riedel, M., Barton, M., Kuhn, M., Lichtlen, P.R., Estrogen dilates human coronary arteries in vitro by an increase in cyclic GMP and cyclic AMP smooth muscle content. European Heart Journal, 14, 1993, 16.
218. Mukherjee, T.K., Dinh, H., Chaudhuri, G., Nathan, L., Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: Implications in atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 99 (2002), 4055–4060, 10.1073/pnas.052703199.
219. Murata, T., Dietrich, H.H., Xiang, C., Dacey, R.G. Jr., G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/reoxygenation injury in male and female rats. Stroke 44 (2013), 779–785, 10.1161/STROKEAHA.112.678177.
220. Nadal, A., Alonso-Magdalena, P., Soriano, S., Quesada, I., Ropero, A.B., The pancreatic beta-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes. Molecular and Cellular Endocrinology 304 (2009), 63–68, 10.1016/j.mce.2009.02.016 S0303-7207(09)00150-6 [pii].
221. Nadal, A., Alonso-Magdalena, P., Soriano, S., Ripoll, C., Fuentes, E., Quesada, I., Ropero, A.B., Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells. Frontiers in Bioscience (Landmark edition) 16 (2011), 251–260.
222. Nadal, A., Alonso-Magdalena, P., Soriano, S., Ropero, A.B., Quesada, I., The role of oestrogens in the adaptation of islets to insulin resistance. The Journal of Physiology 587 (2009), 5031–5037, 10.1113/jphysiol.2009.177188.
223. NCD Risk Factor Collaboration (NCD-RisC), Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387 (2016), 1377–1396, 10.1016/S0140-6736(16)30054-X Erratum in: Lancet, 2016, 387, 1998.
224. Nechmad, A., Merin, G., Schwalb, H., Shimon, D.V., Borman, J.B., Milgalter, E., Mosseri, M., Estrogen induces nitric oxide-mediated vasodilation of human mammary arteries in vitro. Nitric Oxide 2 (1998), 460–466, 10.1006/niox.1998.0202.
225. Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Gakidou, E., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781, 10.1016/S0140-6736(14)60460-8.
226. Novella, S., Heras, M., Hermenegildo, C., Dantas, A.P., Effects of estrogen on vascular inflammation: A matter of timing. Arteriosclerosis, Thrombosis, and Vascular Biology 32 (2012), 2035–2042, 10.1161/ATVBAHA.112.250308.
227. O'Dowd, B.F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K.R., Heng, H.H., George, S.R., Discovery of three novel G-protein-coupled receptor genes. Genomics 47 (1998), 310–313, 10.1006/geno.1998.5095 S0888-7543(98)95095-9 [pii].
228. Ohman, M.K., Luo, W., Wang, H., Guo, C., Abdallah, W., Russo, H.M., Eitzman, D.T., Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 219 (2011), 33–39, 10.1016/j.atherosclerosis.2011.07.012.
229. Olshansky, S.J., Passaro, D.J., Hershow, R.C., Layden, J., Carnes, B.A., Brody, J., Ludwig, D.S., A potential decline in life expectancy in the United States in the 21st century. New England Journal of Medicine 352 (2005), 1138–1145.
230. Orshal, J.M., Khalil, R.A., Gender, sex hormones, and vascular tone. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 286 (2004), R233–R249, 10.1152/ajpregu.00338.2003.
231. Owen, M.K., Witzmann, F.A., McKenney, M.L., Lai, X., Berwick, Z.C., Moberly, S.P., Tune, J.D., Perivascular adipose tissue potentiates contraction of coronary vascular smooth muscle: Influence of obesity. Circulation 128 (2013), 9–18, 10.1161/CIRCULATIONAHA.112.001238.
232. Owman, C., Blay, P., Nilsson, C., Lolait, S.J., Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochemical and Biophysical Research Communications 228 (1996), 285–292.
233. Pelekanou, V., Kampa, M., Kiagiadaki, F., Deli, A., Theodoropoulos, P., Agrogiannis, G., Notas, G., Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERalpha36 and GPR30/GPER1. Journal of Leukocyte Biology 99 (2016), 333–347, 10.1189/jlb.3A0914-430RR.
234. Petrie, W.K., Dennis, M.K., Hu, C., Dai, D., Arterburn, J.B., Smith, H.O., Prossnitz, E.R., G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstetrics and Gynecology International, 2013, 2013, 472720, 10.1155/2013/472720.
235. Pinto, A.R., Ilinykh, A., Ivey, M.J., Kuwabara, J.T., D'Antoni, M.L., Debuque, R., Tallquist, M.D., Revisiting cardiac cellular composition. Circulation Research 118 (2016), 400–409, 10.1161/CIRCRESAHA.115.307778.
236. Pinto, S., Virdis, A., Ghiadoni, L., Bernini, G., Lombardo, M., Petraglia, F., Salvetti, A., Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension 29 (1997), 268–273.
237. Prossnitz, E.R., Arterburn, J.B., International Union of Basic and Clinical Pharmacology. XCVII. G protein-coupled estrogen receptor (GPER) and its pharmacologic modulators. Pharmacological Reviews 67 (2015), 505–540.
238. Prossnitz, E.R., Barton, M., Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins & Other Lipid Mediators 89 (2009), 89–97.
239. Prossnitz, E.R., Barton, M., The G-protein-coupled estrogen receptor GPER in health and disease. Nature Reviews Endocrinology 7 (2011), 715–726, 10.1038/nrendo.2011.122.
240. Prossnitz, E.R., Barton, M., Estrogen biology: New insights into GPER function and clinical opportunities. Molecular and Cellular Endocrinology 389 (2014), 71–83.
241. Rang, S., Wolf, H., Montfrans, G.A., Karemaker, J.M., Non-invasive assessment of autonomic cardiovascular control in normal human pregnancy and pregnancy- associated hypertensive disorders: A review. Journal of Hypertension 20 (2002), 2111–2119.
242. Razandi, M., Pedram, A., Greene, G.L., Levin, E.R., Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Molecular Endocrinology 13 (1999), 307–319, 10.1210/mend.13.2.0239.
243. Razandi, M., Pedram, A., Merchenthaler, I., Greene, G.L., Levin, E.R., Plasma membrane estrogen receptors exist and functions as dimers. Molecular Endocrinology 18 (2004), 2854–2865, 10.1210/me.2004-0115.
244. Recchia, A.G., De Francesco, E.M., Vivacqua, A., Sisci, D., Panno, M.L., Ando, S., Maggiolini, M., The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. The Journal of Biological Chemistry 286 (2011), 10773–10782, 10.1074/jbc.M110.172247.
245. Reis, S.E., Holubkov, R., Zell, K.A., Smith, A.J., Cohen, H.A., Feldman, M.D., Blumenthal, R.S., Estrogen acutely abolishes abnormal cold-induced coronary constriction in men. Chest 114 (1998), 1556–1561.
246. Reslan, O.M., Khalil, R.A., Vascular effects of estrogenic menopausal hormone therapy. Reviews on Recent Clinical Trials 7 (2012), 47–70.
247. Reslan, O.M., Yin, Z., do Nascimento, G.R., Khalil, R.A., Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat. Journal of Cardiovascular Pharmacology 62 (2013), 26–40, 10.1097/FJC.0b013e31828bc88a.
248. Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., Prossnitz, E.R., A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005), 1625–1630.
249. Reynolds, S.R.M., Foster, F.I., Peripheral vascular action of estrogen in the human male. The Journal of Clinical Investigation 18 (1939), 649–655.
250. Riedel, M., Mügge, A., Oestrogen and protection against myocardial ischaemia. Lancet, 342, 1993, 872.
251. Rigiracciolo, D.C., Scarpelli, A., Lappano, R., Pisano, A., Santolla, M.F., Avino, S., De Francesco, E.M., GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget 7 (2016), 94–111, 10.18632/oncotarget.6475.
252. Rosano, G.M., Sarrel, P.M., Poole-Wilson, P.A., Collins, P., Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342 (1993), 133–136.
253. Ross, R., Atherosclerosis—An inflammatory disease. The New England Journal of Medicine 340 (1999), 115–126.
254. Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Ockene, J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002), 321–333.
255. Sadee, W., Pharmacogenomics: Harbinger for the era of personalized medicine?. Molecular Interventions 5 (2005), 140–143, 10.1124/mi.5.3.1.
256. Sakurai, T., Iimuro, S., Araki, A., Umegaki, H., Ohashi, Y., Yokono, K., Ito, H., Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus. Gerontology 56 (2010), 141–149, 10.1159/000246970.
257. Santolla, M.F., De Francesco, E.M., Lappano, R., Rosano, C., Abonante, S., Maggiolini, M., Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cellular Signalling 26 (2014), 1466–1475, 10.1016/j.cellsig.2014.03.011.
258. Santolla, M.F., Lappano, R., De Marco, P., Pupo, M., Vivacqua, A., Sisci, D., Maggiolini, M., G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17beta-estradiol in cancer cells and cancer-associated fibroblasts. The Journal of Biological Chemistry 287 (2012), 43234–43245, 10.1074/jbc.M112.417303.
259. Schenck-Gustafsson, K., Brincat, M., Erel, C.T., Gambacciani, M., Lambrinoudaki, I., Moen, M.H., EMAS, EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 68 (2011), 94–97, 10.1016/j.maturitas.2010.10.005.
260. Scherer, S.W., Cheung, J., MacDonald, J.R., Osborne, L.R., Nakabayashi, K., Herbrick, J.A., Tsui, L.C., Human chromosome 7: DNA sequence and biology. Science 300 (2003), 767–772, 10.1126/science.1083423.
261. Schierbeck, L.L., Rejnmark, L., Tofteng, C.L., Stilgren, L., Eiken, P., Mosekilde, L., Jensen, J.E., Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ, 345, 2012, e6409, 10.1136/bmj.e6409.
262. Sharma, G., Hu, C., Brigman, J.L., Zhu, G., Hathaway, H.J., Prossnitz, E.R., GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology 154 (2013), 4136–4145, 10.1210/en.2013-1357.
263. Sharma, G., Prossnitz, E.R., Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 152 (2011), 3030–3039, 10.1210/en.2011-0091.
264. Sherwood, A., Bower, J.K., McFetridge-Durdle, J., Blumenthal, J.A., Newby, L.K., Hinderliter, A.L., Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 27 (2007), 1782–1787, 10.1161/ATVBAHA.107.145383 ATVBAHA.107.145383 [pii].
265. Simoncini, T., Hafezi-Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W., Liao, J.K., Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000), 538–541.
266. Smith, G.D., A fatter, healthier but more unequal world. Lancet 387 (2016), 1349–1350, 10.1016/S0140-6736(16)00588-2.
267. Soloff, M.S., Szego, C.M., Purification of estradiol receptor from rat uterus and blockade of its estrogen-binding function by specific antibody. Biochemical and Biophysical Research Communications 34 (1969), 141–147.
268. Soltis, E.E., Cassis, L.A., Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clinical and Experimental Hypertension. Part A 13 (1991), 277–296.
269. Somjen, D., Amir-Zaltsman, Y., Gayer, B., Kulik, T., Knoll, E., Stern, N., Kohen, F., 6-Carboxymethyl genistein: A novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus. The Journal of Endocrinology 173 (2002), 415–427.
270. Stauffer, S.R., Coletta, C.J., Tedesco, R., Nishiguchi, G., Carlson, K., Sun, J., Katzenellenbogen, J.A., Pyrazole ligands: Structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. Journal of Medicinal Chemistry 43 (2000), 4934–4947.
271. Steinberg, H.O., Paradisi, G., Cronin, J., Crowde, K., Hempfling, A., Hook, G., Baron, A.D., Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101 (2000), 2040–2046.
272. Stewart, K.G., Zhang, Y., Davidge, S.T., Estrogen decreases prostaglandin H synthase products from endothelial cells. Journal of the Society for Gynecologic Investigation 6 (1999), 322–327.
273. Stewart, S.T., Cutler, D.M., Rosen, A.B., Forecasting the effects of obesity and smoking on U.S. life expectancy. New England Journal of Medicine 361 (2009), 2252–2260, 10.1056/NEJMsa0900459.
274. Stork, S., van der Schouw, Y.T., Grobbee, D.E., Bots, M.L., Estrogen, inflammation and cardiovascular risk in women: A critical appraisal. Trends in Endocrinology and Metabolism 15 (2004), 66–72, 10.1016/j.tem.2004.01.005 S1043276004000062 [pii].
275. Straub, R.H., The complex role of estrogens in inflammation. Endocrine Reviews 28 (2007), 521–574, 10.1210/er.2007-0001 er.2007-0001 [pii].
276. Sudhir, K., Chou, T.M., Chatterjee, K., Smith, E.P., Williams, T.C., Kane, J.P., Rubanyi, G.M., Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96 (1997), 3774–3777.
277. Sudhir, K., Chou, T.M., Messina, L.M., Hutchison, S.J., Korach, K.S., Chatterjee, K., Rubanyi, G.M., Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349 (1997), 1146–1147, 10.1016/S0140-6736(05)63022-X.
278. Sudhir, K., Ko, E., Zellner, C., Wong, H.E., Hutchison, S.J., Chou, T.M., Chatterjee, K., Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 96 (1997), 3626–3632.
279. Takada, Y., Kato, C., Kondo, S., Korenaga, R., Ando, J., Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochemical and Biophysical Research Communications 240 (1997), 737–741.
280. Takahashi, K., Ohmichi, M., Yoshida, M., Hisamoto, K., Mabuchi, S., Arimoto-Ishida, E., Kurachi, H., Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. The Journal of Endocrinology 178 (2003), 319–329.
281. Talwar, G.P., Segal, S.J., Evans, A., Davidson, O.W., The binding of estradiol in the uterus: a mechanism for depression of RNA synthesis. Proceedings of the National Academy of Sciences of the United States of America 52 (1964), 1059–1066.
282. Taylor, C.J., Hobbs, F.D., Heart failure therapy in patients with coronary artery disease. Current Opinion in Pharmacology 13 (2013), 205–209, 10.1016/j.coph.2013.01.009.
283. Thomas, P., Pang, Y., Filardo, E.J., Dong, J., Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005), 624–632.
284. Tiano, J.P., Delghingaro-Augusto, V., Le May, C., Liu, S., Kaw, M.K., Khuder, S.S., Mauvais-Jarvis, F., Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. The Journal of Clinical Investigation 121 (2011), 3331–3342, 10.1172/JCI44564.
285. Tiano, J.P., Mauvais-Jarvis, F., Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nature Reviews Endocrinology 8 (2012), 342–351, 10.1038/nrendo.2011.242.
286. Toh, S., Hernandez-Diaz, S., Logan, R., Rossouw, J.E., Hernan, M.A., Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: Does the increased risk ever disappear? A randomized trial. Annals of Internal Medicine 152 (2010), 211–217, 10.7326/0003-4819-152-4-201002160-00005.
287. Tran, Q.K., Firkins, R., Giles, J., Francis, S., Matnishian, V., Tran, P., Gebert-Oberle, B., Estrogen enhances linkage in the vascular endothelial calmodulin network via a feedforward mechanism at the G protein-coupled estrogen receptor 1. The Journal of Biological Chemistry, 2016, 10.1074/jbc.M115.697334.
288. Traupe, T., Stettler, C.D., Li, H., Haas, E., Bhattacharya, I., Minotti, R., Barton, M., Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 49 (2007), 1364–1370.
289. Tropea, T., De Francesco, E.M., Rigiracciolo, D., Maggiolini, M., Wareing, M., Osol, G., Mandala, M., Pregnancy augments G protein estrogen receptor (GPER) induced vasodilation in rat uterine arteries via the nitric oxide—cGMP signaling pathway. PLoS One, 10, 2015, e0141997, 10.1371/journal.pone.0141997.
290. Turgeon, J.L., McDonnell, D.P., Martin, K.A., Wise, P.M., Hormone therapy: Physiological complexity belies therapeutic simplicity. Science 304 (2004), 1269–1273, 10.1126/science.1096725.
291. Vanhoutte, P.M., Shimokawa, H., Feletou, M., Tang, E.H., Endothelial dysfunction and vascular disease—A thirtieth anniversary update. Acta Physiologica (Oxford, England), 2016, 10.1111/apha.12646 (in press).
292. Vargas, R., Wroblewska, B., Rego, A., Hatch, J., Ramwell, P.W., Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. British Journal of Pharmacology 109 (1993), 612–617.
293. Vergote, I., Abram, P., Fulvestrant, a new treatment option for advanced breast cancer: Tolerability versus existing agents. Annals of Oncology 17 (2006), 200–204, 10.1093/annonc/mdj047.
294. Vickers, M.R., MacLennan, A.H., Lawton, B., Ford, D., Martin, J., Meredith, S.K., WISDOM Group, Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): A randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ, 335, 2007, 239, 10.1136/bmj.39266.425069.AD.
295. Villa, P., Costantini, B., Suriano, R., Perri, C., Macri, F., Ricciardi, L., Lanzone, A., The differential effect of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women: Relationship with the metabolic status. The Journal of Clinical Endocrinology and Metabolism 94 (2009), 552–558, 10.1210/jc.2008-0735.
296. Villablanca, A.C., Tenwolde, A., Lee, M., Huck, M., Mumenthaler, S., Rutledge, J.C., 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. Journal of Cardiovascular Translational Research 2 (2009), 289–299, 10.1007/s12265-009-9103-z.
297. Violin, J.D., Soergel, D.G., Boerrigter, G., Burnett, J.C. Jr., Lark, M.W., GPCR biased ligands as novel heart failure therapeutics. Trends in Cardiovascular Medicine 23 (2013), 242–249, 10.1016/j.tcm.2013.01.002.
298. Virdis, A., Ghiadoni, L., Pinto, S., Lombardo, M., Petraglia, F., Gennazzani, A., Salvetti, A., Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 101 (2000), 2258–2263.
299. Walter, P., Green, S., Greene, G., Krust, A., Bornert, J.M., Waterfield, M., Cloning of the human estrogen receptor cDNA. Proceedings of the National Academy of Sciences of the United States of America 82 (1985), 7889–7893.
300. Wang, H., Jessup, J.A., Lin, M.S., Chagas, C., Lindsey, S.H., Groban, L., Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovascular Research 94 (2012), 96–104, 10.1093/cvr/cvs090.
301. Webb, C.M., Ghatei, M.A., McNeill, J.G., Collins, P., 17beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 102 (2000), 1617–1622.
302. Wendler, A., Albrecht, C., Wehling, M., Nongenomic actions of aldosterone and progesterone revisited. Steroids 77 (2012), 1002–1006, 10.1016/j.steroids.2011.12.023.
303. White, R.E., Estrogen and vascular function. Vascular Pharmacology 38 (2002), 73–80.
304. Williams, J.K., Adams, M.R., Herrington, D.M., Clarkson, T.B., Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. Journal of the American College of Cardiology 20 (1992), 452–457.
305. Wise, P.M., Dubal, D.B., Rau, S.W., Brown, C.M., Suzuki, S., Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's health initiative. Endocrine Reviews 26 (2005), 308–312, 10.1210/er.2004-0014.
306. Witteman, J.C., Grobbee, D.E., Kok, F.J., Hofman, A., Valkenburg, H.A., Increased risk of atherosclerosis in women after the menopause. British Medical Journal 298 (1989), 642–644.
307. Wulfroth, P., Grunwald, J., Differential effect of nicotinic acid derivatives on smooth muscle and endothelial cell proliferation. Basic Research in Cardiology 84 (1989), 291–297.
308. Xiong, X., Xu, L., Wei, L., White, R.E., Ouyang, Y.B., Giffard, R.G., IL-4 is required for sex differences in vulnerability to focal ischemia in mice. Stroke 46 (2015), 2271–2276, 10.1161/STROKEAHA.115.008897.
309. Yoshii, T., Yamada, M., Minami, T., Tsunoda, T., Sasaki, M., Kondo, Y., Terauchi, Y., The effects of bazedoxifene on bone, glucose, and lipid metabolism in postmenopausal women with type 2 diabetes: An exploratory pilot study. Journal of Clinical Medicine Research 7 (2015), 762–769, 10.14740/jocmr2278w.
310. Yu, X., Li, F., Klussmann, E., Stallone, J.N., Han, G., G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. American Journal of Physiology. Endocrinology and Metabolism 307 (2014), E398–E407, 10.1152/ajpendo.00534.2013.
311. Yu, X., Ma, H., Barman, S.A., Liu, A.T., Sellers, M., Stallone, J.N., Han, G., Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. American Journal of Physiology. Endocrinology and Metabolism 301 (2011), E882–E888, 10.1152/ajpendo.00037.2011 ajpendo.00037.2011 [pii].
312. Yue, T.L., Vickery-Clark, L., Louden, C.S., Gu, J.L., Ma, X.L., Narayanan, P.K., Ohlstein, E.H., Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 102 (2000), III281–III288.
313. Yusuf, S., Ounpuu, S., Anand, S., The global epidemic of atherosclerotic cardiovascular disease. Medical Principles and Practice 11 (2002), 3–8.
314. Zhou, P., Pu, W.T., Recounting cardiac cellular composition. Circulation Research 118 (2016), 368–370, 10.1161/CIRCRESAHA.116.308139.